Full video transcriptClick to expand
Auto-generated transcript of @jeremygoodmanmd's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00On TRT, but your nuts are shrinking into raisins. Let's talk about why that is and what you can do
- 0:05about it. You see, when your body stops making its own testosterone production, that's not the only
- 0:10thing that shuts down. We have two types of cells that are found in the testicles,
- 0:13laid-ic cells, they help manufacture testosterone, and sertoli cells, they help manufacture the sperm.
- 0:18It's not the testosterone that's shrinking your balls, meaning not the lack of laid-ic
- 0:22cell activity, but the sertoli cells. So if you have small nuts like raisins, it's because your
- 0:27sertoli cells are just not making sperm. We see this all the time on guys that may have
- 0:31normal testosterone, but they've got small nuts anyhow. So how do you combat this?
- 0:36Typically starting some HCG before you start your TRT. If your nuts are already shut down and
- 0:41are already the size of raisins, you're going to need a lot more HCG to bring them boys back to life.
- 0:45Follow for more MD tips on how to save your nuts.
TRT's hidden side effects: what the science actually shows
Quick answer
Exogenous testosterone suppresses LH and FSH via negative feedback on the HPG axis, reducing both leydig cell testosterone synthesis and sertoli cell-supported spermatogenesis, which together contribute to testicular volume loss. HCG, as an LH analog, can maintain intratesticular testosterone and partially preserve spermatogenesis during TRT, with stronger evidence for concurrent use than for rescue after prolonged suppression. Men concerned about fertility or testicular atrophy should discuss HCG adjunct therapy with a licensed provider before initiating TRT, not after atrophy has already developed.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For TRT's hidden side effects: what the science actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
TRT's hidden side effects: what the science actually shows should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "TRT's hidden side effects: what the science actually shows" from Jeremy Goodman MD. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Exogenous testosterone suppresses LH and FSH via negative feedback on the HPG axis, reducing both leydig cell testosterone synthesis and sertoli cell-supported spermatogenesis, which together contribute to testicular volume loss.
The reason this review is not generic is the source wording and the canonical claim label "trt nobody talks about this trt side effect until it s too late." In this clip, the useful excerpt is: "On TRT, but your nuts are shrinking into raisins." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Exogenous testosterone suppresses LH and FSH via negative feedback on the HPG axis, reducing both leydig cell testosterone synthesis and sertoli cell-supported spermatogenesis, which together contribute to testicular volume loss.
FormBlends verdict
Testosterone evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Exogenous testosterone suppresses LH and FSH via negative feedback on the HPG axis, reducing both leydig cell testosterone synthesis and sertoli cell-supported spermatogenesis, which together contribute to testicular volume loss. HCG, as an LH analog, can maintain intratesticular testosterone and partially preserve spermatogenesis during TRT, with stronger evidence for concurrent use than for rescue after prolonged suppression. Men concerned about fertility or testicular atrophy should discuss HCG adjunct therapy with a licensed provider before initiating TRT, not after atrophy has already developed.
- Both leydig and sertoli cells are suppressed during TRT, not just sertoli cells as the video implies. LH drives leydig cell activity; FSH drives sertoli cell function. Both gonadotropins drop on exogenous testosterone.
- HCG is supported by clinical evidence for preserving testicular volume during TRT. Wenker et al. (2015, Journal of Urology) found concurrent HCG use maintained testicular size compared to TRT alone.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Both leydig and sertoli cells are suppressed during TRT, not just sertoli cells as the video implies. LH drives leydig cell activity; FSH drives sertoli cell function. Both gonadotropins drop on exogenous testosterone.
- HCG is supported by clinical evidence for preserving testicular volume during TRT. Wenker et al. (2015, Journal of Urology) found concurrent HCG use maintained testicular size compared to TRT alone.
- Hsieh et al. (2013, Journal of Urology) found spermatogenesis recovery after testosterone therapy took longer the longer the suppression lasted, and was not guaranteed in all men.
- Normal serum testosterone does not confirm normal testicular function. Testicular volume depends on structural integrity, FSH signaling, and spermatogenic activity, all of which can be impaired independently of serum T levels.
- HCG access has changed since the FDA reclassified it, and not all TRT prescribers routinely offer it. Patients who care about fertility or testicular atrophy need to ask about it explicitly before starting therapy.
- No clinical guideline has established a standard HCG rescue dose for already-atrophied testicles. The claim that more HCG is needed for established atrophy is plausible but not backed by controlled trial data.
- The best time to discuss fertility preservation and HCG adjunct therapy is before starting TRT, when the HPG axis is still intact and responsive.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @jeremygoodmanmd actually say?
The core claim here is that testicular atrophy on TRT is driven by sertoli cell shutdown, not leydig cell shutdown, and that HCG can reverse or prevent it. He says "it's not the testosterone that's shrinking your balls, meaning not the lack of laid-ic cell activity, but the sertoli cells" and that HCG should ideally be started before TRT begins. If atrophy has already occurred, he suggests higher HCG doses will be needed.
He also makes a passing but important claim: men with normal testosterone levels can still have small testicles. This is worth unpacking separately because it's actually one of the more clinically interesting things he says, even if he breezes past it.
Does the science back this up?
Partly, but the sertoli-versus-leydig framing is oversimplified to the point of being misleading. Both cell types are suppressed during exogenous testosterone use, and the distinction he draws is not as clean as he presents it.
When a man takes exogenous testosterone, the hypothalamic-pituitary-gonadal (HPG) axis suppresses LH and FSH. LH is what signals leydig cells to produce testosterone. FSH is what signals sertoli cells to support sperm production. Both signals drop. Both cell types become less active. Testicular volume is a composite of both compartments. Studies by Roth et al. (1971, Journal of Clinical Endocrinology and Metabolism) established decades ago that gonadotropin suppression reduces both leydig and sertoli cell function. More recently, Coviello et al. (2005, Journal of Clinical Endocrinology and Metabolism) confirmed that testosterone suppresses intratesticular testosterone and spermatogenesis together, not one independently of the other.
HCG does work, and the evidence for it is real. It mimics LH, stimulating leydig cells to maintain intratesticular testosterone, which in turn supports sertoli cell function and spermatogenesis. Calof et al. (2005, Journal of Gerontology) and Wenker et al. (2015, Journal of Urology) both support HCG as effective for preserving testicular volume and sperm parameters during TRT.
What did they get wrong (or right)?
The biggest error is framing this as a sertoli-only problem. That's not what the literature says. Testicular atrophy on TRT reflects suppression of the entire HPG-gonadal axis, and both leydig and sertoli cell compartments contribute to testicular volume.
He also mispronounces leydig as "laid-ic," which is minor but doesn't inspire confidence in someone who's about to give clinical guidance.
What he gets right: HCG does preserve testicular volume and fertility potential during TRT. This is well-supported. Starting it before atrophy is established is a reasonable clinical approach. The claim that "guys with normal testosterone can have small nuts" is also accurate. Testicular volume is not solely a testosterone output metric. A man with primary hypogonadism compensating with high LH stimulation, or with a history of orchitis, varicocele, or cryptorchidism, can have small testes and normal serum testosterone.
- Right: HCG preserves testicular volume during TRT
- Right: FSH/sertoli axis matters for sperm production
- Right: Normal testosterone does not guarantee normal testicular size
- Wrong: Framing atrophy as purely a sertoli cell issue
- Wrong: Implying leydig cell activity is not affected by exogenous testosterone
What should you actually know?
If you're on TRT and care about testicular size or fertility, the conversation about HCG needs to happen before you start, not after. The evidence is consistent that concurrent HCG use maintains intratesticular testosterone and spermatogenesis better than trying to restart a fully suppressed axis later.
A 2013 study by Hsieh et al. in the Journal of Urology found that the longer men were on testosterone therapy without HCG, the longer it took to recover spermatogenesis after stopping, and some never fully recovered. That's the actual warning this video should have led with.
HCG is not universally available or cheap, and access has changed significantly since the FDA reclassified it. Many patients on TRT are not offered it routinely. If your provider hasn't discussed fertility preservation or testicular atrophy, that's worth raising directly. FormBlends-affiliated providers can assess whether HCG adjunct therapy is appropriate for your specific situation based on hormone panels and clinical history, not a TikTok algorithm.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Jeremy Goodman MD · TikTok creator
55.1K views on this video
Nobody talks about this TRT side effect… until it’s too late. #T#TRTT#TRTProblemsM#MensHealthT#TestosteroneTruthH#HormoneTherapyT#TRTSideEffectsT#TRTWarningM#MensWellnessF#FitnessFactsT#TRTJourneyT#TRTCommunityH#HealthAlertMenOver30
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about both leydig?
Both leydig and sertoli cells are suppressed during TRT, not just sertoli cells as the video implies. LH drives leydig cell activity; FSH drives sertoli cell function. Both gonadotropins drop on exogenous testosterone.
What does the video say about hcg?
HCG is supported by clinical evidence for preserving testicular volume during TRT. Wenker et al. (2015, Journal of Urology) found concurrent HCG use maintained testicular size compared to TRT alone.
What does the video say about hsieh et al. (2013, journal of urology) found spermatogenesis recovery?
Hsieh et al. (2013, Journal of Urology) found spermatogenesis recovery after testosterone therapy took longer the longer the suppression lasted, and was not guaranteed in all men.
What does the video say about normal serum testosterone does not confirm normal testicular function. testicular?
Normal serum testosterone does not confirm normal testicular function. Testicular volume depends on structural integrity, FSH signaling, and spermatogenic activity, all of which can be impaired independently of serum T levels.
What does the video say about hcg access has changed?
HCG access has changed since the FDA reclassified it, and not all TRT prescribers routinely offer it. Patients who care about fertility or testicular atrophy need to ask about it explicitly before starting therapy.
What does the video say about no clinical guideline has established a standard hcg rescue dose?
No clinical guideline has established a standard HCG rescue dose for already-atrophied testicles. The claim that more HCG is needed for established atrophy is plausible but not backed by controlled trial data.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Jeremy Goodman MD, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.